Analyst Yun Zhong from Wedbush reiterated a Hold rating on Keros Therapeutics (KROS – Research Report) and keeping the price target at $15.00.
Yun Zhong’s rating is based on several factors influencing Keros Therapeutics. The company’s main proprietary program, KER-065, is facing uncertainty due to a lack of detailed information regarding its clinical development plan, including timing and study design. This uncertainty is compounded by the recent decision to shift focus from obesity to neuromuscular disorders, specifically Duchenne Muscular Dystrophy (DMD), which requires further engagement with regulators.
Additionally, while Keros has a strong cash position supported by a significant upfront payment from Takeda, the lack of clarity on the next value driver for KER-065 and the safety concerns in the cibotercept program contribute to the Hold rating. The upcoming data from the cibotercept Phase 2 study may provide insights into safety issues, but until then, the potential risks and uncertainties warrant a cautious approach, justifying the Hold rating and a price target of $15.